MARKET

AMTI

AMTI

Applied Molecular Transport Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.23
+0.39
+4.41%
After Hours: 9.23 0 0.00% 16:01 01/24 EST
OPEN
8.53
PREV CLOSE
8.84
HIGH
9.35
LOW
8.22
VOLUME
279.90K
TURNOVER
--
52 WEEK HIGH
78.22
52 WEEK LOW
8.22
MARKET CAP
289.83M
P/E (TTM)
-3.8156
1D
5D
1M
3M
1Y
5Y
Applied Molecular Transport to Present at Virtual Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Bittoo Kanwar, M.D., chief medical officer, and Liz Bhatt, chief business...
GlobeNewswire · 11/15/2021 13:00
Applied Molecular Transport EPS misses by $0.06
Applied Molecular Transport (NASDAQ:AMTI): Q3 GAAP EPS of -$0.68 misses by $0.06. Cash, cash equivalents and investments of $182.5M Press Release
Seekingalpha · 11/10/2021 22:17
BRIEF-Applied Molecular Transport Posts Quarterly Loss Per Share Of $0.68
reuters.com · 11/10/2021 21:42
Applied Molecular Q3 EPS $(0.68) Down From $(0.48) YoY
Applied Molecular (NASDAQ:AMTI) reported quarterly losses of $(0.68) per share. This is a 41.67 percent decrease over losses of $(0.48) per share from the same period last year.
Benzinga · 11/10/2021 21:27
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 10/15/2021 11:44
Applied Molecular Therapeutics To Present At 3 Upcoming Events In Sept., Oct.: Sept. 22, Oct. 15, Oct. 19
Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in September and October. Details of
Benzinga · 09/17/2021 12:10
Applied Molecular Transport Announces Upcoming Investor Events in September and October
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in Septemb...
GlobeNewswire · 09/17/2021 12:00
We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 09/15/2021 10:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMTI. Analyze the recent business situations of Applied Molecular Transport Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

75.00%Strong Buy
25.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AMTI stock price target is 73.00 with a high estimate of 86.00 and a low estimate of 57.00.
High86.00
Average73.00
Low57.00
Current 9.23
EPS
Actual
Estimate
-0.60-0.45-0.30-0.15
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 91
Institutional Holdings: 26.92M
% Owned: 85.72%
Shares Outstanding: 31.40M
TypeInstitutionsShares
Increased
26
907.10K
New
20
705.46K
Decreased
21
2.93M
Sold Out
9
130.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Non-Executive Chairman/Independent Director
Helen Kim
Chief Executive Officer/Co-Founder/Director
Tahir Mahmood
Co-Founder/Chief Scientific Officer/Director
Randall Mrsny
Chief Financial Officer
Shawn Cross
Senior Vice President - Finance
Brandon Hants
Senior Vice President
Derek Maclean
Senior Vice President
Chuck Olson
Chief Technology Officer
Douglas Rich
Vice President
Andy Whitney
Other
Elizabeth Bhatt
Other
Bittoo Kanwar
Director
Holly Schachner
Independent Director
Graham Cooper
Independent Director
David Lamond
Independent Director
Aaron VanDevender
No Data
  • All
  • Financials
  • Insiders
More
About AMTI
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform, including AMT-101, an oral gastrointestinal (GI)-selective oral fusion of interleukin 10 (IL-10) that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of interleukin 22 (IL-22). Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.

Webull offers kinds of Applied Molecular Transport Inc. stock information, including NASDAQ:AMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMTI stock methods without spending real money on the virtual paper trading platform.